<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201812</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0023</org_study_id>
    <nct_id>NCT00201812</nct_id>
  </id_info>
  <brief_title>Phase I &amp; Biological Study of Etanercept &amp; Weekly Docetaxel in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I &amp; Biological Study of Etanercept &amp; Weekly Docetaxel in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of the combination of Etanercept and Docetaxel in
      patients with advanced solid tumors for which there is no standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose (MTD) of weekly docetaxel in combination with etanercept.</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize toxicities of weekly docetaxel when administered weekly to patients with solid malignancies to determine if co-administration of etanercept can result in higher tolerated doses of docetaxel.</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if weekly docetaxel administration is associated with increased expression of TNF and if inactivation of TNF by etanercept is associated with a decrease in the rate of moderate to severe asthenia.</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminarily evaluate antitumor activity for docetaxel in combination with etanercept.</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.</description>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.</description>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.</description>
    <other_name>steriod</other_name>
    <other_name>glucocorticoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have pathologically or cytologically confirmed advanced solid malignancy for
             which there is no standard treatment exists.

          -  Solid malignancy that has persisted or recurred following prior therapy or advanced
             solid malignancy for which docetaxel is considered an acceptable first line treatment
             option:

               -  Non-Small Cell Lung

               -  Breast

               -  Head and Neck

               -  Esophageal

               -  Stomach

               -  Ovarian carcinomas

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

          -  Life expectancy of at least 12 weeks.

          -  Must have adequate organ function

          -  Peripheral Neuropathy must be less than Grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Villalona</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20;24(12):1852-9.</citation>
    <PMID>16622259</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

